MODERN APPROACHES TO ASSESSING TREATMENT EFFECTIVENESS IN PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE ASSOCIATED WITH TYPE 2 DIABETES MELLITUS
Ключевые слова:
Type 2 diabetes mellitus, NAFLD, fatty liver, Nigella sativa, hepatoprotectionАннотация
The coexistence of type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) represents a significant clinical and public health challenge due to their high prevalence and shared pathophysiological mechanisms. The present study aimed to evaluate the effectiveness of different therapeutic approaches and to develop comprehensive criteria for assessing treatment outcomes in patients with T2DM combined with fatty liver disease. A total of 85 patients aged 20–55 years were included in the study and divided into four groups depending on the treatment strategy. The findings demonstrated that combined therapy, including Nigella sativa and Protecto-Hepar in addition to standard treatment, resulted in a more pronounced improvement in clinical condition, biochemical parameters, and liver function compared to standard therapy alone. The highest treatment effectiveness (95.4%) and the shortest recovery period (16±1.0 days) were observed in the combined therapy group. These results indicate that a pathogenetically justified combined therapeutic approach significantly improves treatment outcomes in this category of patients
##plugins.themes.default.displayStats.downloads##
Библиографические ссылки
1. American Diabetes Association. Standards of Care in Diabetes—2024. Diabetes Care. 2024.
2. Anstee Q.M., et al. From NASH to HCC. Nat Rev Gastroenterol Hepatol. 2019;16:411–428.
3. Armstrong M.J., et al. Liraglutide in NASH. Lancet Gastroenterol Hepatol. 2016;1(2):156–167.
4.Byrne C.D., Targher G. NAFLD and cardiometabolic disease. Clinical Science. 2020;134:877–904.
5. Cusi K. Treatment of T2DM and NAFLD. Diabetes Care. 2020;43(11):2809–2823.
6. EASL–EASD–EASO Guidelines. Journal of Hepatology. 2016;64(6):1388–1402.
7. Eslam M., et al. MAFLD definition. Journal of Hepatology. 2020;73(1):202–209.
8. Gastaldelli A., et al. Hepatic steatosis and insulin resistance. Journal of Hepatology. 2021;75(2):420–433.
9. Geller L.I., Gladkikh L.N., Gryaznova M.V. Treatment of fatty liver in patients with diabetes mellitus. Problems of Endocrinology. 1993;39(5):20–22.
10. Kiseleva E.V., Demidova T.Yu. NAFLD and type 2 diabetes mellitus.
11. Mantovani A., et al. NAFLD and risk of T2DM. Diabetes Care. 2018;41(2):372–382.
12. Pankiv V.I. Type 2 diabetes mellitus and NAFLD. International Endocrinology Journal. 2013.
13. Polyzos S.A., Mantzoros C.S. Metabolic syndrome and NAFLD. Metabolism. 2019;92:82–97.
14. Rodionova S.V., Zvenigorodskaya L.A., Biryukova E.V. NAFLD and T2DM. Consilium Medicum. 2016;18(8).
15. Shimizu M., et al. SGLT2 inhibitors and liver fibrosis. Hepatology Research. 2019;49(5):531–539.
